$7.85
+8.28%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.42
From 52W high−53.55%
Volume245152.00
Market cap$109.95M
P/E (TTM)—
P/S (TTM)8010.0x
Div yield—
Key dataOct 19, 2026
Open
$7.42
From 52W high
−53.55%
Volume
245152.00
Market cap
$109.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.9x
P/E (TTM)
—
RSI (14)
33.3
MomentumView details →
1D Return
+8.28%
YTD Return
+10.74%
SummaryUpdated Dec 1, 2025
Kazia Therapeutics Limited (NASDAQ:KZIA) is an Australian oncology-focused biotechnology company that develops anti-cancer drugs for treating various forms of cancer. Originally incorporated in 1994 as Novogen Limited, the company rebranded to Kazia Therapeutics in November 2017 to better reflect its focus on cancer therapeutics. Based in Sydney, Australia, Kazia went public in 1999 and has been dedicated to advancing novel cancer treatments through clinical development, with particular emphasis on brain-penetrant therapies for difficult-to-treat cancers like glioblastoma.
Similar companies
Latest newsMore news →
Sovargen Co., Ltd. dosed the first patient in a Phase 1b/2a trial of Paxalisib for rare seizure disorders, triggering a $2 million payment to Kazia Therapeutics.27d agoKazia Therapeutics announced that the first patient has been dosed in Arm A of the PNOC035 Phase 2 clinical study evaluating paxalisib in combination with gemcitabine for recurrent or progressive AT/RT brain cancer in patients aged 1 to 39.40d agoKazia Therapeutics expanded its paxalisib clinical trial into HR+/HER2- breast cancer.48d ago